化療間插聯(lián)合EGFR-TKIs對比單獨化療一線治療晚期非小細胞肺癌的Meta分析
發(fā)布時間：2018-10-17 17:20
【摘要】：目的:化療與表皮生長因子受體酪氨酸激酶抑制劑(epidermal growth factor receptor-tyrosine kinase inhibitors,EGFR-TKIs)聯(lián)合療法一直是許多研究的焦點,其中間插聯(lián)合療法受到了更多研究者的關(guān)注。本研究旨在系統(tǒng)評價化療與EGFR-TKIs間插聯(lián)合療法對比單獨化療一線治療晚期非小細胞肺癌(non-small cell lung cancer,NSCLC)的有效性及安全性。方法:檢索The Cochrane Library、Pub Med、EMBASE、中國生物醫(yī)學文獻數(shù)據(jù)庫(CBM)、知網(wǎng)和萬方等數(shù)據(jù)庫關(guān)于化療間插聯(lián)合EGFR-TKIs療法對比單獨化療一線治療晚期NSCLC的隨機對照試驗(randomized controlled trial,RCT),分析如下結(jié)局指標:無進展生存期(progression free survival,PFS)、總體生存期(overall survival,OS)、客觀緩解率(objective response rate,ORR)、疾病控制率(disease control rate,DCR)以及不良反應發(fā)生率。由兩名研究者根據(jù)Cochrane系統(tǒng)評價手冊篩選文獻、進行質(zhì)量評價以及提取并交叉核對數(shù)據(jù)。應用Stata12.0軟件進行meta分析。結(jié)果:本研究共納入6個RCT,共計933例晚期NSCLC患者。Meta分析結(jié)果表明,在晚期NSCLC患者一線治療中,與單獨化療相比,間插聯(lián)合療法雖然延長了患者的PFS(HR=0.72,95%CI=0.53-0.98,P=0.037),但并不能提高其OS(HR=0.85,95%CI=0.72-1.01,P=0.060)、ORR(OR=1.59,95%CI=0.86-2.95,P=0.142)和DCR(OR=1.09,95%CI=0.95-1.25,P=0.226)。進一步的亞組分析發(fā)現(xiàn),間插聯(lián)合療法顯著提高了女性、腺癌、從不吸煙和EGFR突變等患者的PFS,差異具有統(tǒng)計學意義。在安全性方面,間插聯(lián)合療法的主要不良反應為皮疹(OR=7.81,95%CI=3.74-16.34,P=0.000)和腹瀉(OR=2.73,95%CI=1.92-3.89,P=0.000)。結(jié)論:一線接受化療間插聯(lián)合EGFR-TKIs治療的NSCLC患者的PFS明顯高于接受單獨化療者,其主要不良事件是皮疹和腹瀉。因此,間插聯(lián)合治療具有一定優(yōu)勢,但仍需要更多大樣本、高質(zhì)量的RCT進一步驗證。
[Abstract]:Objective: chemotherapy combined with epidermal growth factor receptor tyrosine kinase inhibitor (epidermal growth factor receptor-tyrosine kinase inhibitors,EGFR-TKIs) has been the focus of many studies. The purpose of this study was to evaluate the efficacy and safety of chemotherapy and EGFR-TKIs interventional therapy in the treatment of advanced non-small cell lung cancer (non-small cell lung cancer,NSCLC). Methods: a randomized controlled trial (randomized controlled trial,RCT) of The Cochrane Library,Pub Med,EMBASE, Chinese biomedical literature database, (CBM), Zhiwang and Wanfang, on the comparison of chemotherapeutic interventional therapy with EGFR-TKIs therapy in late stage NSCLC was conducted. The results were analyzed as follows. Outcome measures: progression-free survival (progression free survival,PFS), total survival (overall survival,OS), objective remission rate (objective response rate,ORR), disease control rate (disease control rate,DCR) and adverse reactions. According to the Cochrane system evaluation manual, two researchers sifted the literature, evaluated the quality, extracted and cross-checked the data. Meta analysis was carried out with Stata12.0 software. Results: in this study, 933 patients with advanced NSCLC were included in 6 RCT, patients. The results of Meta analysis showed that in the first-line treatment of advanced NSCLC patients, the intercalation combined therapy could not improve the OS (HR=0.85,95%CI=0.72-1.01,P=0.060), ORR (OR=1.59,95%CI=0.86-2.95,P=0.142) and DCR (OR=1.09,95%CI=0.95-1.25,P=0.226), although it prolonged the PFS (HR=0.72,95%CI=0.53-0.98,P=0.037) of the patients compared with chemotherapy alone. Further subgroup analysis showed that interventional therapy significantly increased PFS, in women, adenocarcinoma, non-smoking and EGFR mutation. In terms of safety, the main adverse effects of interventional therapy were skin rash (OR=7.81,95%CI=3.74-16.34,P=0.000) and diarrhea (OR=2.73,95%CI=1.92-3.89,P=0.000). Conclusion: the PFS of NSCLC patients treated with interventional chemotherapy plus EGFR-TKIs was significantly higher than that of patients treated with chemotherapy alone. The main adverse events were rash and diarrhea. Therefore, interventional therapy has some advantages, but still needs more large samples, high quality RCT further verification.
【學位授予單位】：重慶醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R734.2
本文編號：2277397
[Abstract]:Objective: chemotherapy combined with epidermal growth factor receptor tyrosine kinase inhibitor (epidermal growth factor receptor-tyrosine kinase inhibitors,EGFR-TKIs) has been the focus of many studies. The purpose of this study was to evaluate the efficacy and safety of chemotherapy and EGFR-TKIs interventional therapy in the treatment of advanced non-small cell lung cancer (non-small cell lung cancer,NSCLC). Methods: a randomized controlled trial (randomized controlled trial,RCT) of The Cochrane Library,Pub Med,EMBASE, Chinese biomedical literature database, (CBM), Zhiwang and Wanfang, on the comparison of chemotherapeutic interventional therapy with EGFR-TKIs therapy in late stage NSCLC was conducted. The results were analyzed as follows. Outcome measures: progression-free survival (progression free survival,PFS), total survival (overall survival,OS), objective remission rate (objective response rate,ORR), disease control rate (disease control rate,DCR) and adverse reactions. According to the Cochrane system evaluation manual, two researchers sifted the literature, evaluated the quality, extracted and cross-checked the data. Meta analysis was carried out with Stata12.0 software. Results: in this study, 933 patients with advanced NSCLC were included in 6 RCT, patients. The results of Meta analysis showed that in the first-line treatment of advanced NSCLC patients, the intercalation combined therapy could not improve the OS (HR=0.85,95%CI=0.72-1.01,P=0.060), ORR (OR=1.59,95%CI=0.86-2.95,P=0.142) and DCR (OR=1.09,95%CI=0.95-1.25,P=0.226), although it prolonged the PFS (HR=0.72,95%CI=0.53-0.98,P=0.037) of the patients compared with chemotherapy alone. Further subgroup analysis showed that interventional therapy significantly increased PFS, in women, adenocarcinoma, non-smoking and EGFR mutation. In terms of safety, the main adverse effects of interventional therapy were skin rash (OR=7.81,95%CI=3.74-16.34,P=0.000) and diarrhea (OR=2.73,95%CI=1.92-3.89,P=0.000). Conclusion: the PFS of NSCLC patients treated with interventional chemotherapy plus EGFR-TKIs was significantly higher than that of patients treated with chemotherapy alone. The main adverse events were rash and diarrhea. Therefore, interventional therapy has some advantages, but still needs more large samples, high quality RCT further verification.
【學位授予單位】：重慶醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R734.2
【參考文獻】
相關(guān)期刊論文 前9條
1 洪超煜;梅同華;;特羅凱對晚期非小細胞肺癌患者的有效性與安全性[J];牡丹江醫(yī)學院學報;2016年06期
2 曹飛飛;張琳琳;王雙;鐘殿勝;王燕;;EGFR-TKIs與化療比較一線治療非小細胞肺癌療效的meta分析[J];中國肺癌雜志;2015年03期
3 李亞楠;王洪武;;抑癌基因PTEN與非小細胞肺癌相關(guān)性研究進展[J];中國肺癌雜志;2014年03期
4 王強;馬玲;申紅麗;張濤;袁帥飛;俞婷婷;單莉;;培美曲塞聯(lián)合鉑類一線治療晚期NSCLC療效與安全性Meta分析[J];中華腫瘤防治雜志;2014年01期
5 張濤;袁帥飛;王子平;張茜;趙盼盼;單莉;;貝伐單抗聯(lián)合化療治療非小細胞肺癌的meta分析[J];中國肺癌雜志;2013年02期
6 黃巖;劉云鵬;周建英;徐農(nóng);李寶蘭;伍鋼;方健;李凱;劉曉睛;劉巍;盧鈾;王孟昭;劉文超;梁后杰;張沂平;黃誠;王順金;王雅杰;于世英;常建華;王哲海;胡志皇;張力;;培美曲塞聯(lián)合順鉑對比吉西他濱聯(lián)合順鉑一線治療晚期非鱗非小細胞肺癌的隨機、對照、多中心臨床研究[J];中國肺癌雜志;2012年10期
7 過雪丹;吳福林;陳暑波;徐偉;黃慶;;吉西他濱聯(lián)合順鉑序貫吉非替尼治療晚期非小細胞肺癌[J];現(xiàn)代生物醫(yī)學進展;2012年09期
8 張文穎;張為民;王林;鄭靜嫻;肖鋒;;多西他賽與吉非替尼序貫應用對人肺腺癌細胞SPC-A1生長及信號蛋白的影響[J];中國肺癌雜志;2011年05期
9 郭繼武;馬彬;周慧銀;王瑤;張圓;;吉非替尼治療非小細胞肺癌的meta分析[J];中國肺癌雜志;2011年04期
，本文編號：2277397
本文鏈接：http://sikaile.net/yixuelunwen/zlx/2277397.html
最近更新
教材專著
